Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by Piper Sandler

Humacyte (NASDAQ:HUMA)‘s stock had its “neutral” rating reissued by research analysts at Piper Sandler in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $4.00 price target on the stock. Piper Sandler’s price target would indicate a potential upside of 29.03% from the company’s previous close.

A number of other equities research analysts have also commented on the stock. Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Monday. HC Wainwright began coverage on Humacyte in a research note on Monday, December 11th. They issued a “buy” rating and a $6.00 target price on the stock.

Humacyte Trading Up 1.0 %

Shares of HUMA stock opened at $3.10 on Tuesday. Humacyte has a 52-week low of $1.96 and a 52-week high of $5.60. The business’s fifty day moving average is $3.53 and its 200 day moving average is $2.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 6.79. The company has a market capitalization of $362.27 million, a PE ratio of -2.90 and a beta of 1.53.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the firm posted ($0.21) EPS. On average, equities research analysts anticipate that Humacyte will post -0.95 EPS for the current fiscal year.

Institutional Trading of Humacyte

A number of hedge funds have recently bought and sold shares of HUMA. BlackRock Inc. grew its position in shares of Humacyte by 13.2% during the second quarter. BlackRock Inc. now owns 4,304,505 shares of the company’s stock worth $12,311,000 after purchasing an additional 501,265 shares in the last quarter. Vanguard Group Inc. grew its holdings in Humacyte by 3.5% during the 4th quarter. Vanguard Group Inc. now owns 3,123,266 shares of the company’s stock valued at $8,870,000 after buying an additional 104,299 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Humacyte by 4.6% in the second quarter. Geode Capital Management LLC now owns 1,101,967 shares of the company’s stock worth $3,152,000 after buying an additional 48,034 shares in the last quarter. State Street Corp boosted its position in shares of Humacyte by 57.3% during the second quarter. State Street Corp now owns 1,039,280 shares of the company’s stock worth $2,972,000 after acquiring an additional 378,485 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Humacyte by 9.0% in the fourth quarter. Northern Trust Corp now owns 565,107 shares of the company’s stock worth $1,605,000 after buying an additional 46,521 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).